Administration of DSR-29133 led to the induction of IFNα/γ, IP-10, TNFα, IL-1Ra and IL-12p70.Combined therapy resulted in curative responses in a high proportion of mice bearing established CT26 tumours which was dependent on the activity of CD8+ T-cells, but independent of CD4+ T-cells and NK/NKT cells. Long-term surviving mice treated with combination were protected from subsequent tumour rechallenge. This evidence concerns the gene CD8A and neoplasm.